Speaking Out on the Promise of Diagnostics
Executive SummaryEmery Stephans, the head of Enterprise Analysis, a consultancy focused on in vitro diagnostics and medical imaging, observes that the in vitro diagnostics industry is slow growing and has only limited resources to spend on development of next-generation products. Nevertheless, he's optimistic about the future, and excited by the promise of pharmacogenomics, analyte specific reagents,and consumerism, which he believes will act as driving forces in diagnostics.
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.